CN101244202B - 一种中药口服固体制剂及其制备方法、含量测定方法和用途 - Google Patents
一种中药口服固体制剂及其制备方法、含量测定方法和用途 Download PDFInfo
- Publication number
- CN101244202B CN101244202B CN2008100453186A CN200810045318A CN101244202B CN 101244202 B CN101244202 B CN 101244202B CN 2008100453186 A CN2008100453186 A CN 2008100453186A CN 200810045318 A CN200810045318 A CN 200810045318A CN 101244202 B CN101244202 B CN 101244202B
- Authority
- CN
- China
- Prior art keywords
- preparation
- radix
- silica gel
- micropowder silica
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 64
- 239000007787 solid Substances 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title claims description 26
- 238000003908 quality control method Methods 0.000 title abstract description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 48
- 239000008187 granular material Substances 0.000 claims abstract description 37
- 239000000741 silica gel Substances 0.000 claims abstract description 36
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 32
- 230000000694 effects Effects 0.000 claims abstract description 20
- 239000000284 extract Substances 0.000 claims abstract description 19
- 229920001353 Dextrin Polymers 0.000 claims abstract description 16
- 239000004375 Dextrin Substances 0.000 claims abstract description 16
- 235000019425 dextrin Nutrition 0.000 claims abstract description 16
- 229920002472 Starch Polymers 0.000 claims abstract description 14
- 239000008107 starch Substances 0.000 claims abstract description 14
- 235000019698 starch Nutrition 0.000 claims abstract description 14
- 230000008569 process Effects 0.000 claims abstract description 10
- 238000001514 detection method Methods 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 claims description 37
- 238000012360 testing method Methods 0.000 claims description 35
- 239000013558 reference substance Substances 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 26
- 102000004877 Insulin Human genes 0.000 claims description 21
- 108090001061 Insulin Proteins 0.000 claims description 21
- 229940125396 insulin Drugs 0.000 claims description 21
- 239000002671 adjuvant Substances 0.000 claims description 20
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 13
- 238000003556 assay Methods 0.000 claims description 12
- 238000005469 granulation Methods 0.000 claims description 11
- 230000003179 granulation Effects 0.000 claims description 11
- 239000009636 Huang Qi Substances 0.000 claims description 9
- 230000004060 metabolic process Effects 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 238000000889 atomisation Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 238000005550 wet granulation Methods 0.000 claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000007670 refining Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 11
- 239000006187 pill Substances 0.000 abstract description 8
- 239000002775 capsule Substances 0.000 abstract description 7
- 239000000377 silicon dioxide Substances 0.000 abstract description 6
- 239000003826 tablet Substances 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 241000411851 herbal medicine Species 0.000 abstract 1
- 239000000047 product Substances 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 16
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000008103 glucose Substances 0.000 description 7
- 239000000945 filler Substances 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000000703 high-speed centrifugation Methods 0.000 description 5
- 201000008980 hyperinsulinism Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000011003 system suitability test Methods 0.000 description 5
- 238000001291 vacuum drying Methods 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 4
- 235000019700 dicalcium phosphate Nutrition 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 101150037123 APOE gene Proteins 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- MONUPUTUEMYISZ-UHFFFAOYSA-K C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Mg+2].C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Mg+2].C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Mg+2] Chemical compound C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Mg+2].C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Mg+2].C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Mg+2] MONUPUTUEMYISZ-UHFFFAOYSA-K 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-ASMJPISFSA-N alpha-maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-ASMJPISFSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
序号 | 辅料及配比 |
1 2 3 4 5 6 7 8 | 淀粉 糊精 微粉硅胶 微晶纤维素 淀粉∶磷酸氢钙=5∶2 糊精∶磷酸氢钙=5∶2 淀粉∶微粉硅胶=3∶4 糊精∶微粉硅胶=3∶4 |
编号 | 吸湿性考察结果 | 流动性 | 可压性 |
1 2 3 4 5 6 7 8 | +++ +++ + ++ +++ +++ ++ ++ | 较差 较差 好 较好 较差 较差 较好 好 | 一般 较好 一般 一般 一般 一般 好 较好 |
实验号 | R1 | R2 | R3 | R4 | R5 |
制剂辅料(g) 吸湿性 流动性 可压性 | 50 +++ 较差 好 | 75 ++ 较好 好 | 100 + 好 较好 | 125 + 好 较好 | 150 - 好 差 |
技术参数 | A | B | C |
喷雾频率 压力(MPa) 物料温度(℃) 进风温度(℃) 出风温度(℃) 制粒情况 | 4HZ 0.08~0.16 20~40 85 65 成粒性较差,较难制粒 | 4HZ 0.2~0.4 40~60 95 75 可制粒,制粒时间较长 | 4HZ 0.08~0.16 60~80 105 85 易制粒,颗粒均匀 |
H2SO4∶H2O(V∶V) | 相对湿度(%) | 吸湿百分率(%) |
79.6∶100 69.4∶100 59.2∶100 49.1∶100 38.9∶100 28.7∶100 18.5∶100 | 20 30 40 50 60 70 80 | 1.83 2.72 3.59 5.18 8.46 15.97 25.13 |
实验号 | 辅料种类 | 辅料加量(以占颗粒总重量的 百分率表示) | 抗粘着性能 | 可压性 |
1 2 3 4 5 6 | 硬脂酸镁 硬脂酸镁 硬脂酸镁 滑石粉 滑石粉 滑石粉 | 0.1% 0.3% 0.5% 1% 3% 5% | 较差 一般 较好 较差 一般 较好 | 较好 较好 较好 较好 较好 较好 |
进样量(μg) | 0.1957 | 0.3914 | 0.7828 | 1.5656 | 3.1312 |
峰面积 | 139215 | 273987 | 535036 | 1109295 | 2190186 |
时间 | 0小时 | 2小时 | 4小时 | 6小时 | 8小时 | RSD% |
峰面积 | 572370 | 578441 | 582754 | 572689 | 581903 | 0.85 |
编号 | 1 | 2 | 3 | 4 | 5 | 平均 | RSD% |
芍药苷含量 (mg/g) | 2.79 | 2.81 | 2.77 | 2.83 | 2.79 | 2.80 | 0.85 |
编 号 | 样品中含芍 药苷量(mg) | 加入芍药 苷量(mg) | 测得总量 (mg) | 测得量 (mg) | 回收率 (%) | 平均回收率 (%) | RSD (%) |
1 2 3 4 5 | 0.4021 0.4068 0.4007 0.3993 0.3928 | 0.4336 0.4336 0.4336 0.4336 0.4336 | 0.8177 0.8286 0.8208 0.8215 0.8097 | 0.4156 0.4218 0.4202 0.4222 0.4169 | 95.86 97.28 96.90 97.37 96.14 | 96.71 | 0.70 |
分钟 | 对照组 | 1%组 | 2%组 |
70 80 90 | 84.5±13.6 87.5±15.9 87.5±15.9 | 105.2±16.3 104.7±23.8 104.7±23.8 | 114.6±29.5 116.0±31.3 116.0±31.3 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100453186A CN101244202B (zh) | 2008-01-31 | 2008-01-31 | 一种中药口服固体制剂及其制备方法、含量测定方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100453186A CN101244202B (zh) | 2008-01-31 | 2008-01-31 | 一种中药口服固体制剂及其制备方法、含量测定方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101244202A CN101244202A (zh) | 2008-08-20 |
CN101244202B true CN101244202B (zh) | 2011-11-23 |
Family
ID=39945023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100453186A Active CN101244202B (zh) | 2008-01-31 | 2008-01-31 | 一种中药口服固体制剂及其制备方法、含量测定方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101244202B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010135858A1 (zh) * | 2009-05-25 | 2010-12-02 | 成都中汇制药有限公司 | 药物组合物及其在制备药剂中的用途 |
CN106581277A (zh) * | 2017-02-13 | 2017-04-26 | 佛山市腾瑞医药科技有限公司 | 一种治疗糖尿病的中药组合物及其制备方法 |
CN110742864A (zh) * | 2018-10-16 | 2020-02-04 | 陕西中医药大学附属医院 | 一种改性中药浸膏粉的制备方法 |
CN113082182A (zh) * | 2021-04-12 | 2021-07-09 | 刘淑娥 | 一种治疗糖尿病的中药 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1840081A (zh) * | 2006-01-23 | 2006-10-04 | 北京因科瑞斯生物制品研究所 | 一种糖脉康片及其制备方法 |
-
2008
- 2008-01-31 CN CN2008100453186A patent/CN101244202B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1840081A (zh) * | 2006-01-23 | 2006-10-04 | 北京因科瑞斯生物制品研究所 | 一种糖脉康片及其制备方法 |
Non-Patent Citations (2)
Title |
---|
国家药典委员会.糖脉康颗粒.《国家药品监督管理局药品标准第二十六册》.2000,1028. * |
江涛.不同赋形剂对心脉神胶囊沸腾干燥制粒的影响.《中国药房》.2007,第18卷(第18期),1387. * |
Also Published As
Publication number | Publication date |
---|---|
CN101244202A (zh) | 2008-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100536870C (zh) | 一种新复方大青叶制剂的检测方法 | |
CN1876040B (zh) | 治疗肝炎的药物制剂的检测方法 | |
CN101274025A (zh) | 一种具有清热泻火解毒作用的中药组合物及其制备方法和质量控制方法 | |
CN101002909B (zh) | 抗病毒中药制剂及其制备方法和质控方法 | |
CN101011527B (zh) | 一种橘红丸的改型制剂及其制备方法 | |
CN101313936A (zh) | 一种疏风止痛的药物组合物及制备方法和质量控制方法 | |
CN1803180B (zh) | 一种药物组合物及其制备方法和质量控制方法 | |
CN101244202B (zh) | 一种中药口服固体制剂及其制备方法、含量测定方法和用途 | |
CN100389816C (zh) | 一种治疗高脂血症的藏药制剂及其制备方法 | |
CN100477985C (zh) | 一种脑心清分散片及其制备工艺 | |
CN105535428A (zh) | 一种天王补心制剂的制作方法 | |
CN103735712B (zh) | 一种中药组合物的制备方法及其制备的中药组合物 | |
CN1923263B (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN100376287C (zh) | 半夏泻心汤制剂及其制备方法和应用 | |
CN101933996B (zh) | 一种具有清热泻火解毒作用的中药组合物及其制备方法和检测方法 | |
CN1857445B (zh) | 一种得生制剂的检测方法 | |
CN100585401C (zh) | 降脂排毒口服制剂的检测方法 | |
CN101879271B (zh) | 橘红胶囊的质量检测方法 | |
CN102284021B (zh) | 一种小儿宣肺止咳颗粒组合物及其制备方法和质量检测方法 | |
CN101485736B (zh) | 一种具有化石、排石作用的药物组合物及其制备方法 | |
CN100522198C (zh) | 前列安通胶囊的检测方法 | |
CN1695713B (zh) | 一种治疗糖尿病的药物及其制备和质量控制方法 | |
CN101584676B (zh) | 一种苦参素缓释制剂及其制备方法 | |
CN100453114C (zh) | 一种治疗病毒性感冒的中药组合物及其制备方法 | |
CN101371890B (zh) | 一种治疗乳腺增生、乳腺癌的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SICHUAN SUNNYHOPE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHONGHUI PHARMACEUTICAL CO., LTD., CHENGDU CITY Effective date: 20120203 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610036 CHENGDU, SICHUAN PROVINCE TO: 610041 CHENGDU, SICHUAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120203 Address after: No. 3 high tech Zone Gaopeng road in Chengdu city of Sichuan Province in 610041 Patentee after: Sichuan Sunnyhope Pharmaceutical Co., Ltd. Address before: 610036 No. 30 Shu West Road, Sichuan, Chengdu Patentee before: Zhonghui Pharmaceutical Co., Ltd., Chengdu City |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Chinese medicine oral administration solid preparations, preparation, quality control method and uses thereof Effective date of registration: 20141120 Granted publication date: 20111123 Pledgee: China Huarong Asset Management Limited by Share Ltd Sichuan branch Pledgor: Sichuan Sunnyhope Pharmaceutical Co., Ltd. Registration number: 2014510000035 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180209 Granted publication date: 20111123 Pledgee: China Huarong Asset Management Limited by Share Ltd Sichuan branch Pledgor: Sichuan Sunnyhope Pharmaceutical Co., Ltd. Registration number: 2014510000035 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180718 Address after: 611130 Wenjiang District, Chengdu, Sichuan, Chengdu, 66 science and Technology Industrial Development Park, Collins Road Patentee after: Sichuan Bao Jian pharmacy Co., Ltd. Address before: No. 3 high tech Zone Gaopeng road in Chengdu city of Sichuan Province in 610041 Patentee before: Sichuan Sunnyhope Pharmaceutical Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 611130 Wenjiang District, Chengdu, Sichuan, Chengdu, 66 science and Technology Industrial Development Park, Collins Road Patentee after: Chengdu Beite Danuo Pharmaceutical Co.,Ltd. Address before: 611130 Wenjiang District, Chengdu, Sichuan, Chengdu, 66 science and Technology Industrial Development Park, Collins Road Patentee before: Sichuan Bao Jian pharmacy Co.,Ltd. |